Chuankuhuang Powder is supplied as a desiccated, multi-marker botanical extract whose veterinary-grade specification must be confirmed against the batch certificate before formulation development. The application routes below are restricted to those dosage forms listed in the product scope—tablets, injections, capsules, powders, granules, premix, and solutions—and do not extend to non-veterinary use. All addition ratios are expressed on a dried-substance basis and require normalization to the assay content of the particular batch. Published data for this specific configuration is limited; therefore scale-up from laboratory trials to commercial lines requires a retained-sample stability study under the intended packaging.

Compression-Grade Limitations at High Dose and High Humidity

Tablet manufacture using Chuankuhuang Powder places the greatest demand on moisture control and particle-size distribution, not on the active content itself. The API is typically received with a loss-on-drying value in the range of 4.0–6.5%; if the value exceeds 6.0% at the time of weighing, a tray-drying step at 40–45°C for 90–120 min is introduced before sifting through an 80-mesh (180 µm) stainless-steel vibratory screen. In a direct-compression formulation, the API is loaded at 12.5–25.0 wt% of the core tablet weight, with microcrystalline cellulose PH102 making up 50–65 wt%, sodium starch glycolate 2.0–4.0 wt%, colloidal silicon dioxide 0.5–1.0 wt%, and magnesium stearate 0.5–1.0 wt%. For high-dose tablets requiring 40–60 wt% API, direct compression is not suitable because the extract’s fibrous fraction reduces powder permeability and causes lamination on rotary presses operating above 15 kN main compression force. The downstream process for high-dose cores therefore uses wet granulation with purified water or 2–5% povidone K30 solution in a high-shear mixer, followed by fluid-bed drying to residual moisture 2.0–3.5%, dry milling through a 1.0 mm screen, and final blending. Tablet compression is performed on an instrumented rotary press with 8 mm round or 10 mm flat-faced bevel-edge tooling, precompression force 4–6 kN, main compression force 8–14 kN, and target hardness 60–100 N measured according to Ph. Eur. 2.9.8. Friability is controlled below 1.0% after 100 revolutions using the method of USP <1216>; disintegration is evaluated in water at 37±2°C with a limit of not more than 15 min according to USP <701> and Ph. Eur. 2.9.1. For product registered in China, the core formulation is assessed against the tablet general monograph of the Chinese Veterinary Pharmacopoeia 2020 General Chapter 0101. The terminal product type is an immediate-release veterinary tablet for oral administration, packed in PVC/PVDC/aluminum blister cavities with a desiccant canister when the product is shipped to markets where ambient humidity exceeds 60% RH.

What Changes When the Same API Enters a Sterile Injectable Process?

Aseptic processing of Chuankuhuang Powder for parenteral administration is constrained by the same phytochemical instability that affects oral solid dosage forms, but the control burden shifts from moisture and flow to bioburden, pyrogen, particulate load, and filter binding. The API is dissolved or suspended in water for injection at 0.5–2.0% w/v in the finished solution; higher loadings are not pursued until a solubility screen demonstrates no precipitation at 2–8°C and 25°C over 72 h. A formulation trial usually includes sodium chloride 0.85–0.90% w/v, pH adjustment with 0.1 M hydrochloric acid or sodium hydroxide to a target of 5.5–6.5, and, when required by the marketing authorization file, 0.1–0.5% w/v antioxidant such as sodium metabisulfite. The compounding order is critical: the extract is pre-wetted with a small volume of WFI in a high-shear disperser at 1500–3000 rpm for 15–20 min, then transferred into a 1000 L stainless-steel jacketed tank under nitrogen blanketing at 20–25°C. The solution is clarified through a 0.45 µm polypropylene depth filter and sterilized by passage through a 0.22 µm polyvinylidene fluoride or polyethersulfone cartridge that has been validated for bacterial retention according to ASTM F838-20. Filling is performed in an isolator or restricted access barrier system meeting EU GMP Annex 1 (2022) Grade A conditions, with the surrounding area meeting ISO 14644-1:2015 Class 5 at rest and Class 7 in operation. Terminal sterilization is avoided when accelerated stability data show marker loss above 10% after 121°C for 15 min. The terminal product is a sterile injectable solution in 10 mL, 20 mL, or 50 mL Type I glass vials with chlorobutyl stoppers, intended for intramuscular or subcutaneous administration to the target species defined in the registration file.

The most consequential production failure observed on a multi-head aseptic filling line is the appearance of visible particles after the solution is held for more than 4 h in a tank that was previously used for an acetate-buffered product. If turbidity exceeds 2 NTU or the filter pressure differential rises above 0.8 bar at 25°C, the batch should be quarantined and the API batch re-assayed. Published filter-binding data for the specific marker compounds in Chuankuhuang Powder is limited; a small-scale filtration compatibility study using the actual batch is therefore required before scale-up.

Capsule filling with Chuankuhuang Powder is assigned to an automatic tamping-pin machine only after the API has been pre-dispersed in a high-shear mixer; the unmilled extract tends to smear the dosing disc and causes plug weight variation when the powder’s loss-on-drying exceeds 5.5%. The formulation addition ratio is 12.5–50.0 wt% of the total fill weight, with lactose monohydrate or mannitol as the main diluent, croscarmellose sodium 2.0–5.0 wt% as disintegrant, colloidal silicon dioxide 0.5–1.0 wt% as glidant, and magnesium stearate 0.5–1.0 wt% as lubricant. A size 0 hard gelatin capsule with a fill weight of 350–450 mg can accommodate 50–150 mg of API; the exact ratio must be normalized to the assay value on the certificate of analysis. The downstream production sequence is: sift the API through a 60-mesh (250 µm) screen, blend in a 1000 L bin blender at 6–10 rpm for 15–20 min, pass the blend through a 1.0 mm screen to break soft agglomerates, blend again for 5 min, and fill on a tamping-pin encapsulation machine operating at 20,000–30,000 capsules per hour with tamping pin force 5–15 N. Capsule fill weight is checked every 15 min using a 20-capsule sample; individual fill weight tolerance is ±5%. Capsule weight uniformity is assessed according to Ph. Eur. 2.9.5 and USP <905>; disintegration is tested in 0.1 M hydrochloric acid at 37±2°C with a limit of not more than 20 min according to Ph. Eur. 2.9.1 and USP <701>. The terminal product is a hard gelatin capsule for oral veterinary administration, packed in HDPE bottles with induction-sealed caps and a desiccant; storage below 35% RH is avoided because the capsule shell can become brittle and split during transport.

For mass oral administration to poultry or pigs through drinking water, a plain powder formulation of Chuankuhuang Powder is not sufficient because the extract’s hydrophobic surface forms a floating film when the water hardness exceeds 150 ppm as CaCO₃ and the product temperature falls below 15°C. The preferred downstream form is a water-dispersible granule produced by top-spray fluid-bed granulation. The API is loaded at 10–25 wt% of the granule formulation, with lactose monohydrate 50–70 wt%, povidone K30 2.0–5.0 wt%, croscarmellose sodium 3.0–5.0 wt%, and citric acid 1.0–2.0 wt% to buffer the reconstituted solution to pH 4.5–5.5. The granulation solution is sprayed at a rate of 150–250 g/min in a fluid-bed dryer with a 120 L bowl, inlet air temperature 60–70°C, product temperature 30–35°C, atomization air pressure 1.5–2.0 bar, and final moisture 2.0–4.0%; atomization air complies with ISO 8573-1:2010 Class 2 for water and oil. The dried granules are sized through a 1000 µm screen and the 100–300 µm fraction is retained for packaging because finer material causes dusting during farm transfer. The finished granule is dosed into drinking water at 0.5–1.0 g/L or into complete feed at 100–500 g/tonne; the addition ratio for the API in the final medicated water is therefore 0.05–0.25 g/L, depending on the registered target-species dose. Compliance for the granule itself follows the general monograph for granules of the Chinese Veterinary Pharmacopoeia 2020, particle-size distribution is measured by analytical sieving according to Ph. Eur. 2.9.12, and dissolution performance is checked by a vessel test with 500 mL water at 20±2°C and paddle speed 75 rpm: complete dispersion must occur within 3 min with no visible agglomerates retained on a 180 µm sieve. The terminal product is a water-soluble granule packed in 100 g, 500 g, or 1 kg laminated foil sachets, intended for dilution before oral administration.

If the API Is Assigned to a Low-Dose Medicated Premix, Mixer Validation Becomes the Binding Constraint

Chuankuhuang Powder used in a veterinary premix has a different risk profile from a direct oral formulation: the active-bearing particles must survive repeated dilution into feed carriers without electrostatic separation, dust migration, or moisture-induced caking. The intermediate premix is formulated at 2.0–5.0 wt% API on a suitable mineral or vegetable carrier, such as ground limestone or wheat middlings, with 0.5–1.0 wt% vegetable oil added as a dust suppressant. This intermediate premix is then incorporated into complete feed at 2–10 kg/tonne, delivering 100–500 g API per tonne of final feed or 100–500 ppm active substance in the feed. The governing compliance framework is EU Regulation 2019/4 on medicated feed and, for facilities supplying the US market, FDA 21 CFR 225.1 under current good manufacturing practice for medicated feeds. Mixer validation must follow ISO 6497:2002 for sampling, with not fewer than 10 samples taken from the mixer and the first, middle, and end of discharge. The acceptance criterion for blend uniformity is a relative standard deviation not greater than 5.0% and mean recovery between 95% and 105% of theoretical. Production experience shows that the largest source of batch failure is not the mixer itself but the sack-tip hopper: the API’s bulk density can vary from 0.45 g/cm³ to 0.65 g/cm³ between supplier batches, and when the hopper is fitted with a narrow cone angle below 60°, the powder can bridge and deliver a low first-in load that skews the initial 2–3 min of mixing. The premix line should therefore use a vented hopper with a 70° cone angle and a pneumatic hammer set to activate only when the load-cell mass flow falls below 80% of setpoint. Molasses-based carriers are avoided unless the molasses has been dried to a water activity below 0.60. The terminal product is a medicated premix in 25 kg multi-wall paper bags with an inner polyethylene liner; it is diluted into final feed at the farm or feed mill and must not be used in feed for species outside the registration.

A concentrated oral solution of Chuankuhuang Powder is prepared when the farm requires a liquid dosing system or when a drinking-water medication must be dispensed through a proportioner pump. The API is first milled to a particle size below 180 µm and dispersed in a high-shear mixer with 2.0–5.0 wt% polysorbate 80 or another nonionic wetting agent; the concentrated solution contains 1.0–4.0 wt% API, 0.1 M citrate buffer at pH 4.5–5.5, 0.1–0.2% w/v potassium sorbate as preservative, and purified water q.s. The final use concentration in drinking water is 0.05–0.20 g/L, achieved by a 1:100 dilution step in the proportioner. The production process uses a 500 L stainless-steel tank with a bottom-mounted high-shear disperser at 1500–3000 rpm for 20 min, followed by passage through a 50 µm inline strainer and filling into 1 L, 5 L, or 20 L HDPE containers with induction-sealed closures. The liquid is non-sterile; microbiological quality must comply with Ph. Eur. 5.1.4 and USP <61> and <62> for total aerobic microbial count and specified absence of Escherichia coli and Salmonella. If the product is intended as a multidose container with use beyond 24 h after first opening, preservative efficacy is evaluated according to USP <51>. A pH drift above 6.5 during storage can cause precipitation of polyphenolic fractions and should be corrected with additional citrate buffer rather than sodium bicarbonate, because bicarbonate can release carbon dioxide and pressurize the sealed container. Solutions diluted at the farm should be used within 24 h unless the concentrated product contains a validated preservative system under the intended temperature range. The terminal product is an oral solution for drinking-water medication in poultry or swine, and it is never administered by injection.